Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has entered into an exclusive research and development collaboration agreement with TMS NeuroHealth Centers Inc. (“TMS”). TMS is a wholly owned subsidiary of Greenbrook TMS Inc. (TSX: … Continue reading →

CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observedStifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distributionReport incorporates both … Continue reading →

Cybin (NEO: CYBN) (OTCQB: CLXPF) is a leading biotechnology company focused on progressing psychedelic therapeutics. The company has announced that its Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, … Continue reading →

Decision represents opportunity to help millions suffering from social, generalized anxiety disordersGlobal markets will reach an estimated $4 billion this year, with significant growth projected looking forwardWHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have … Continue reading →

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced its newest Clinical Advisory Board member: Dr. Thomas Laughren. A former director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the … Continue reading →

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in the upcoming Life Sciences Investor Forum, scheduled for June 24, 2021. During the presentation, Cybin’s CEO Doug Drysdale will provide an overview of … Continue reading →

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has completed its 51st preclinical study; the study is a critical step in the company’s progress in the Investigational New Drug (“IND”) process. The … Continue reading →

Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced that its CEO Doug Drysdale will be participating at the 2021 Emerging Growth Conference, which is scheduled for June 23, 2021.As part of his participation, Drysdale will be presenting a live webcast featuring … Continue reading →

The study will examine treating symptoms of depression, anxiety, burnout and post-traumatic stressEMBARK is groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicineCybin considers it an honor, duty to support healing processes of doctors, … Continue reading →